TB-500 and the actin-binding fragment
A short sequence carries an interesting molecular motif. The much larger protein supplies most of the repair literature.
Seven amino acids from a longer protein
TB-500 is the synthetic acetylated sequence Ac-LKKTETQ, corresponding to positions 17–23 of thymosin beta-4. The fragment has 7 amino acids; the parent protein has 43. Those are different experimental materials.
The actin structure study examined a gelsolin-domain-1–thymosin beta-4 hybrid bound to actin. It explained how the thymosin arrangement caps an actin unit, preventing assembly into a filament. The review of the full protein places that interaction in the broader biology of cell migration.
I imagined TB-500 as a compact copy of the protein. Its sequence made that picture too comfortable: identifying an actin-binding region leaves open how the isolated fragment behaves in living tissue. The experiments have to carry that answer.
Wound resurfacing in rats
In the 1999 rat wound experiment, full thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline. Re-epithelialization means resurfacing the wound with epithelial cells. The study also found greater wound contraction, collagen deposition and angiogenesis.
That is a rich set of animal measurements. The researchers recorded several changes beneath the visible surface. That thoroughness earns my respect. It remains a rat wound experiment with the full protein; it supplies no clinical result for the TB-500 fragment in a muscle tear.
The human study used full thymosin beta-4
The randomized Phase 1 intravenous study enrolled 40 healthy volunteers. The tested amounts reached 1,260 mg, given first as a single dose and then daily for two weeks. Full thymosin beta-4 was well tolerated, with infrequent mild or moderate adverse events and no dose-limiting toxicities or serious adverse events. Phase 1 work asks early questions about safety and how the substance behaves in the body.
Neither a human injury nor the isolated TB-500 fragment was the subject of that trial. For me, its most useful contribution is the boundary it makes visible: there is human safety work in this protein family, and its experimental material has a precise identity. The 2026 sports-medicine review still describes scarce rigorous human safety evidence for unapproved repair peptides.
Rat stroke response to thymosin beta-4
The rat stroke dose-response study used full thymosin beta-4. Treatment began 24 hours after the stroke. Two tested amounts improved neurological function from day 14 through day 56. The highest tested amount gave no significant benefit. This was a rat brain-injury model. It cannot establish a TB-500 treatment or a human schedule.
That uneven response is exactly the sort of result a broad repair label obscures. Experimental conditions suddenly matter a great deal. The name of the molecule alone leaves too much out.
TB-500 reports and sports status
Anecdotal accounts describe tendon, ligament or muscle improvement, easier movement and less joint stiffness. Redness, swelling or aching at an injection site, tiredness, headache and nausea are also reported. These are community stories, not controlled clinical evidence, and they provide no reliable frequency or established safe amount.
TB-500 has no FDA approval and is prohibited in sport. Long-term human safety for the fragment remains unknown, and research-labelled material can have uncertain identity and purity. The safety questions discuss the theoretical blood-vessel concern and the uncertainty around cancer. GLOW and KLOW carry this fragment question into mixtures with still more variables.